Invesco Nasdaq Biotechnology ETF

IBBQ
ETF Ticker

+23.17%

+36.13%

NASDAQ

Equity

United States

Sector

ETF Strategy Fund Grade A

The Invesco Nasdaq Biotechnology ETF, IBBQ_US, is listed on the NASDAQ and tracks the Nasdaq Biotechnology index. The fund provides exposure to United States, Sector Equity and has assets under management of $96.3m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Jun 11, 2021. It has a net expense ratio of 19bps. (All data in USD as of Oct 15, 2026 unless stated.)

The underlying Nasdaq Biotechnology Index targets Nasdaq-listed biotechnology and pharmaceutical companies classified under the Industry Classification Benchmark. Eligible securities are common and ordinary shares and ADRs listed on Nasdaq, excluding preferred and other non-ordinary issues, and must meet Nasdaq’s minimum market-capitalization, trading-volume and seasoning requirements, which constrain inclusion of smaller or thinly traded names. The universe is limited to issuers whose primary business is biotechnology or pharmaceuticals, with periodic classification reviews to maintain sector purity. Constituents are weighted by float-adjusted market cap using Nasdaq’s modified market-cap methodology, which applies single-stock and aggregate caps so that the largest holdings cannot dominate index risk while preserving a broadly market-cap-proportional profile. The index is reconstituted annually in December to refresh membership for new listings, delistings and reclassifications, and it is rebalanced quarterly in March, June, September and December to update shares and reapply concentration caps.

ETF Details

Key Facts

Issuer:
Invesco
AUM:
$96.3m (as of Aug 31, 2026)
Net Expense Ratio:
19 bps
Inception Date:
Jun 11, 2021
Index:
Nasdaq Biotechnology Index
Dividend Frequency:
Quarterly

Trading

Ticker:
IBBQ
Exchange:
NASDAQ
ISIN:
US46138G5999
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
United States
Theme:
Sector
Economic Development:
Developed Markets
1 Year Volatility:
22.16%
3 Year Volatility:
21.10%
5 Year Volatility:
22.21%

Performance

TTM Dividend Yield:
1.52% (verify with issuer)
1 Month Performance:
1.87%
3 Month Performance:
6.96%
6 Month Performance:
15.65%
1 Year Performance:
36.13%
3 Year Performance:
81.70%
5 Year Performance:
46.75%
Investment Proposition

Invesco Nasdaq Biotechnology ETF (IBBQ) provides focused exposure to biotechnology companies listed on the Nasdaq, emphasizing firms developing novel therapeutics, diagnostics, tools, and genomic platforms. The strategy tracks a rules-based selection of pure-play biotech businesses, accepting higher single-name and industry concentration to pursue idiosyncratic innovation-led returns, with turnover driven primarily by eligibility changes and corporate actions rather than discretionary trades. The portfolio’s style skews toward growth and early-stage profitability, making performance sensitive to clinical trial outcomes, regulatory decisions, capital-markets conditions, and shifts in real rates that influence long-duration equity valuations. Income is typically incidental, with most cash flow reinvested in R&D. As a portfolio tool, it fits as a satellite thematic sleeve for innovation exposure, a factor-completion tilt within healthcare, or a tactical overlay around drug-development and approval cycles. Investors most suited are return-seeking allocators comfortable with event risk and drawdown volatility, or thematic mandates seeking targeted healthcare innovation. Regimes with ample risk appetite, supportive funding, and easing rate pressures tend to favor it; broad risk-off or tightening cycles can challenge it. Key risk: elevated event concentration from binary clinical and regulatory milestones.

ETF Analytics

Fund Discovery

4 Suggestions